Trial Condition(s):
Advanced Non-Small Cell Lung Cancer, Cancer
Expanded access to provide BAY2927088 for the treatment of locally advanced or metastatic NSCLC with HER2 mutation
Bayer Identifier:
22913
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Recruiting
Trial Purpose
The purpose of this Expanded Access Program (EAP) is to allow patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the human epidermal growth factor receptor 2 (HER2) gene, which have no other therapeutic option, to receive BAY2927088.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
N/A
Trial Dates
N/A
N/A
Phase
N/A
Could I receive a placebo?
No
Products
BAY2927088
Accepts Healthy Volunteers
N/A
Where to Participate
Locations
Status
| Locations | Status |
|---|
For details, please refer to trial results
Additional Information
Copyright © Bayer
Powered by
